Targeting CD19 with genetically modified EBV-specific human T lymphocytes

Annals of Hematology

Volumn 81, Issue SUPPL. 2, 2002, Pages

  Roessig, C ^a   Scherer, S P ^a   Baer, A ^a   Vormoor, J ^a   Rooney, C M ^b   Brenner, M K ^b   Juergens, H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DNA MODIFICATION; EFFECTOR CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LEUKEMIA; LYSIS; MINIMAL RESIDUAL DISEASE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD19; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; NEOPLASM, RESIDUAL; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSFECTION;

EID: 0036990306     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Woolfrey AE et al. (2002) Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 99:2002-2008
2. Eshhar Z, Waks T, Gross G, and Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Nat lAcad Sci USA 90:720-724
3. Nadler LM et al. (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131:244-250
4. Heslop HE et al. (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551-555
5. Rooney CM et al. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein- Barr-virus-related lymphoproliferation. Lancet 345:9-13
6. Rooney CM et al. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549-1555
7. Zola H et al. (1991) Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 69 (Pt 6), 411-422
8. Nicholson IC et al. (1997) Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 34:1157-1165
9. Riviere I, Brose K, and Mulligan RC (1995) Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 92:6733-6737
10. Rooney CM et al. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13